Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1633
This examiner grants 21% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18176871 | DESTABILIZED ARE 3'UTRs AS THERAPEUTICS FOR CANCER | Non-Final OA | President and Fellows of Harvard College |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | Final Rejection | THE BROAD INSTITUTE, INC. |
| 18458139 | Skin Probiotics | Non-Final OA | The Regents of the University of California |
| 17925470 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18022415 | METHOD FOR IN VITRO PRODUCTION OF RED BLOOD CELLS | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18274133 | PHOTO-CROSSLINKED BIOREDUCIBLE POLYMERIC NANOPARTICLES FOR ENHANCED RNA DELIVERY | Non-Final OA | The Johns Hopkins University |
| 15327794 | SUBSET-OPTIMIZED CHIMERIC ANTIGEN RECEPTOR-CONTAINING T-CELLS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17918887 | ENHANCING AAV-MEDIATED DELIVERY AND TRANSDUCTION WITH POLYVINYL ALCOHOL | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18088544 | POLYMERIC NANOPARTICLES AND DERIVATIVES THEREOF FOR NUCLEIC ACID BINDING AND DELIVERY | Final Rejection | University of Massachusetts |
| 18307258 | METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING TUBB2B | Non-Final OA | City University of Hong Kong |
| 17765507 | METHOD FOR PRODUCING HEPARIN-LIKE SUBSTANCE, RECOMBINANT CELL, AND METHOD FOR PRODUCING THE SAME | Final Rejection | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 16973603 | COMPOSITIONS AND METHODS FOR IN VIVO POST TRANSLATIONAL MODIFICATION | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18433277 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | Non-Final OA | Seattle Children's Hospital, dba Seattle Children's Research Institute |
| 18431597 | Liver Specific Delivery of Messenger RNA | Final Rejection | Translate Bio, Inc. |
| 18334330 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | Final Rejection | Translate Bio, Inc. |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Final Rejection | Translate Bio, Inc. |
| 17829271 | Low Molecular Weight Silk Compositions and Stabilizing Silk Compositions | Final Rejection | Trustees of Tufts College |
| 18310969 | COMPOSITION FOR PREVENTING OR TREATING PROGERIA AND NATURAL AGING THROUGH GENE EDITING | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18547809 | COMPOSITION AND METHODS FOR THE TREATMENT OF FABRY DISEASE | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18471761 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | Final Rejection | Board of Regents of The University of Texas System |
| 18172176 | PRODUCTION OF EXTRACELLULAR VESICLES IN SINGLE-CELL SUSPENSION USING CHEMICALLY-DEFINED CELL CULTURE MEDIA | Final Rejection | LONZA SALES AG |
| 18278570 | IMMUNOEVASIVE ANTI-TUMOR ADENOVIRUS | Non-Final OA | CURIGIN CO., LTD. |
| 16813263 | Methods of Generating Mature Human Muscle Fibers | Non-Final OA | University of Maryland, Baltimore |
| 17913743 | RNA PARTICLES COMPRISING POLYSARCOSINE | Non-Final OA | BIONTECH SE |
| 18033535 | EXOSOMES CONTAINING MIRNAS TARGETING HER2 SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | Non-Final OA | IMMVIRA CO., LIMITED |
| 18036472 | GENETICALLY ENGINEERED YEAST CELLS AND METHODS OF USE THEREOF | Non-Final OA | Berkeley Fermentation Science Inc. |
| 18003646 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18184965 | COMPOSITIONS AND METHODS FOR CONTROLLING BLOOD SUGAR LEVELS USING NANOCAPSULE-BASED DRUG DELIVERY SYSTEM | Final Rejection | VL Biotech Inc. |
| 18179269 | METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS | Non-Final OA | Institut National de la Santé et de la Recherche Medicale (INSERM) |
| 18176259 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | Final Rejection | CYTONUS THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy